Drug eluting mesh to prevent infection of indwelling transdermal devices

1. A system comprising:

an implanted transdermal medical device; and

a device comprising a mesh having at least one bioresorbable polymer coating, said coating comprising at least one active agent which is eluted over time, and said device being positioned in and around an injection port of the implanted transdermal medical device, wherein the implanted transdermal device is a gastric lap band.

2. The system of claim 1 , wherein the device comprising the mesh is porous.

3. The system of claim 1 , wherein the device comprising the mesh is formed from knitted, braided, woven or non-woven fibers.

4. The system of claim 1 , wherein the mesh is formed of at least one bioresorbable polymer.

5. The system of claim 1 , wherein the at least one bioresorbable polymer coating comprises a tyrosine-derived polyesteramide.

6. The system of claim 5 , wherein the tyrosine-derived polyesteramide is a member of the P22 family of tyrosine-derived polyesteramides.

7. The system of claim 6 , wherein a percentage of free acid in the P22 family of tyrosine-derived polyesteramides ranges from about 5% to about 40%.

8. The system of claim 6 , wherein a percentage of free acid in the P22 family of tyrosine-derived polyesteramide is about 27.5%.

9. The system of claim 1 , wherein the coating comprises a tyrosine-derived polyesteramide and at least one polymer selected from the group consisting of polylactic acid, polyglycolic acid, poly(L-lactide) (PLLA), poly(D,L-lactide) (PLA) polyglycolic acid [polyglycolide (PGA)], poly(L-lactide-co-D,L-lactide) (PLLA/PLA), poly(L-lactide-co-glycolide) (PLLA/PGA), poly(D, L-lactide-co-glycolide) (PLA/PGA), poly(glycolide-co-trimethylene carbonate) (PGA/PTMC), poly(D,L-lactide-co-caprolactone) (PLA/PCL), poly(glycolide-co-caprolactone) (PGA/PCL), poly(oxa)esters, polyethylene oxide (PEO), polydioxanone (PDS), polypropylene fumarate, polyethyl glutamate-co-glutamic acid), poly(tert-butyloxy-carbonylmethyl glutamate), polycaprolactone (PCL), polycaprolactone co-butylacrylate, polyhydroxybutyrate (PHBT), polyhydroxybutyrate, poly(phosphazene), poly(phosphate ester), poly(amino acid), polydepsipeptides, polyiminocarbonates, poly[(97.5% dimethyl-trimethylene carbonate)-co-(2.5% trimethylene carbonate)], poly(orthoesters), tyrosine-derived polycarbonates, tyrosine-derived polyiminocarbonates, tyrosine-derived polyphosphonates, polyethylene oxide, polyalkylene oxides, and hydroxypropylmethylcellulose.

10. The system of claim 1 , wherein the active agent is an antimicrobial agent, an anesthetic, a procoagulant agent, or an anti-inflamatory agent.

11. The system of claim 10 , wherein the antimicrobial agent is selected from the group consisting of antibiotics, antiseptics, and disinfectants.

12. The system of claim 11 , wherein the antibiotic is selected from the group consisting of tetracyclines, penicillins, macrolides, rifampin and combinations thereof.

13. The system of claim 12 , wherein the antibiotic comprises a combination of minocycline and rifampin.

14. The system of claim 1 , wherein said active agent is released from said coating over about a 24 hour time period.

15. The system of claim 1 , wherein said active agent is released from said coating over about a 48 hour time period.

16. The system of claim 1 , wherein said active agent is released from said coating over about a 120 hour time period.

17. The system of claim 1 , wherein said active agent is rifampin, minocycline, or a mixture thereof and wherein at least about 60% of said rifampin, minocycline, or a mixture thereof is released within about 24 to about 36 hours.

18. The system of claim 1 , wherein said active agent is minocycline and a tissue concentration of said minocycline is selected from the group consisting of between about 0.65 μg/mL and 0.8 μg/mL after about 2 hours, about 2.55 μg/mL and about 2.75 μg/mL after about 6 hours, and about 1.2 μg/mL and about 1.9 μg/mL after about 24 hours.

19. The system of claim 1 , wherein said active agent is minocycline and a tissue concentration of said minocycline is between about 0.65 μg/mL and about 0.8 μg/mL after about 2 hours; where the tissue concentration of said minocycline is between about 2.55 μg/mL and about 2.75 μg/mL after about 6 hours; and where the tissue concentration of said minocycline is between about 1.2 μg/mL and about 1.9 μg/mL after about 24 hours.

20. The system of claim 1 , wherein said active agent is rifampin and a tissue concentration of said rifampin is selected from the group consisting of between about 0.6 μg/mL and 1.4 μg/mL after about 2 hours, about 1.9 μg/mL and about 2.3 μg/mL after about 6 hours, and about 2.6 μg/mL and about 4.2 μg/mL after about 24 hours.

21. The system of claim 1 , wherein said active agent is rifampin and a tissue concentration of said rifampin is between about 0.6 μg/mL and 1.4 μg/mL after about 2 hours; where the tissue concentration of said rifampin is between about 1.9 μg/mL and about 2.3 μg/mL after about 6 hours; and where the tissue concentration of said rifampin is between about 2.6 μg/mL and about 4.2 μg/mL after about 24 hours.

22. The system of claim 1 , wherein said active agent achieves a level equal or exceeding a minimum inhibitory concentration of said active agent for methicillin-resistant Staphylococcus aureus on both sides of said implanted transdermal medical device for at least about 24 hours after implantation of said implanted transdermal medical device.

23. The system of claim 1 , wherein said active agent achieves a level equal or exceeding a minimum inhibitory concentration of said active agent for methicillin-resistant Staphylococcus aureus on both sides of said implanted transdermal medical device for at least about 48 hours after implantation of said implanted transdermal medical device.

24. The system of claim 1 , wherein the mesh prevents tissue in-growth from a tissue surrounding the implanted transdermal device.

25. A system comprising:

a gastric lap band; and

a composition comprising at least one bioresorbable polymer, the composition comprising rifampin and minocycline which is eluted over time, the composition being positioned in and around an injection port of the gastric lap band.

26. The system of claim 25 , wherein the composition is a formulation selected from the group consisting of a putty, a paste, a gel, a foam, an ointment, and a cream.

27. The system of claim 25 , wherein an amount of the at least one bioresorbable polymer ranges from about 30% to about 80% by weight of the composition.

28. The system of claim 25 , wherein the at least one bioresorbable polymer is a tyrosine-derived polyesteramide.

29. A method of reducing infection in tissue surrounding a gastric lap band, the method comprising: eluting an active agent from a composition or device wherein the device comprises a mesh having at least one bioresorbable polymer coating, wherein the active agent is eluted from the composition or the coating over time and the composition or device is positioned in and around an injection port of the gastric lap band.

30. The method of claim 29 , wherein the active agent is an antimicrobial agent, an anesthetic, a procoagulant agent, or an anti-inflamatory agent.